ERBB2 and breast carcinoma: In this study, we compared the ADCC and CDC activity of H2Mab-250 and trastuzumab and found that H2Mab-250 exhibited a superior CDC activity against breast cancer and HER2-overexpressed cells compared to trastuzumab (Figure 1, Figure 2 and Figure 4).